MedTrace Logo

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

NCT01190475 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-10-27

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

Active treatment with a high dose of BGS649

DRUG

Active treatment with a low dose of BGS649

DRUG

Placebo treatment to blind study

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Mereo BioPharma

    lead INDUSTRY

Principal Investigators

  • Jacqueline Parkin, PhD FRCP · Mereo BioPharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01190475 on ClinicalTrials.gov